As of late April 2026, the biotechnology sector is experiencing a significant resurgence, driven by robust clinical pipelines, increasing M&A activity, and a strong rebound in investor appetite for risk. Analysts currently highlight high-conviction buy opportunities including Vertex Pharmaceuticals, BioMarin, Exelixis, and Intellia Therapeutics, alongside promising, high-growth picks like Halozyme and Alnylam. For more details, visit The Motley Fool . Vertex Pharmaceuticals
Enter your name and email below and you'll be the first to know when our new app launches.
Enter your name and email below and we'll send it right over.
Enter your name and email below and we'll send it right over.
Enter your name and email below and we'll send it right over.
Enter your name and email below and we'll send it right over.
Enter your name and email below and we'll send it right over.
Enter your name and email below and we'll send it right over.
Enter your name and email below and we'll send it right over.